bioAffinity Technologies, Inc. SEC filings BIAF
bioAffinity Technologies, Inc. has 399 filings in SEC EDGAR's recent list, going back to Jul 26, 2017. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Filing | Oct 13, 2026 | — |
| EFFECT | Filing | Sep 4, 2026 | — |
| EFFECT | Filing | Jun 16, 2026 | — |
| CORRESP | Letter to the SEC | Jun 12, 2026 | — |
| EFFECT | Filing | May 12, 2026 | — |
| CORRESP | Letter to the SEC | May 11, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| UPLOAD | Letter from the SEC | May 7, 2026 | — |
| DRS | Filing | Apr 30, 2026 | — |
| PRER14A | Filing | Oct 27, 2025 | — |
| EFFECT | Filing | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| CORRESP | Letter to the SEC | Sep 24, 2025 | — |
| EFFECT | Filing | Sep 16, 2025 | — |
| CORRESP | Letter to the SEC | Sep 16, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| DRS | Filing | Aug 22, 2025 | — |
| EFFECT | Filing | Jul 3, 2025 | — |
| EFFECT | Filing | Jul 3, 2025 | — |
| PRER14A | Filing | May 23, 2025 | — |
| EFFECT | Filing | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 2, 2025 | — |
| CORRESP | Letter to the SEC | May 2, 2025 | — |
| EFFECT | Filing | Apr 18, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 18, 2025 | — |
| CORRESP | Letter to the SEC | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2025 | — |
| DRSLTR | Filing | Apr 15, 2025 | — |
| DRS | Filing | Apr 15, 2025 | — |
| EFFECT | Filing | Dec 6, 2024 | — |
| CORRESP | Letter to the SEC | Dec 4, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2024 | — |
| D | Filing | Oct 29, 2024 | — |
| EFFECT | Filing | Sep 19, 2024 | — |
| CORRESP | Letter to the SEC | Sep 17, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2024 | — |
| D | Filing | Aug 12, 2024 | — |
| D | Filing | Aug 12, 2024 | — |
| EFFECT | Filing | Apr 15, 2024 | — |
| CORRESP | Letter to the SEC | Apr 11, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2024 | — |
| EFFECT | Filing | Apr 5, 2024 | — |
| D | Filing | Mar 20, 2024 | — |
| EFFECT | Filing | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Nov 22, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| RW | Filing | Sep 25, 2023 | — |
| DRS | Filing | Aug 14, 2023 | — |
| EFFECT | Filing | Aug 29, 2022 | — |
| CORRESP | Letter to the SEC | Aug 26, 2022 | — |
| CORRESP | Letter to the SEC | Aug 26, 2022 | — |
| CORRESP | Letter to the SEC | Aug 25, 2022 | — |
| CORRESP | Letter to the SEC | Aug 25, 2022 | — |
| CORRESP | Letter to the SEC | Aug 24, 2022 | — |
| CORRESP | Letter to the SEC | Aug 24, 2022 | — |
| CORRESP | Letter to the SEC | Aug 23, 2022 | — |
| CORRESP | Letter to the SEC | Aug 23, 2022 | — |
| CORRESP | Letter to the SEC | Aug 23, 2022 | — |
| CORRESP | Letter to the SEC | Aug 23, 2022 | — |
| 8-A12B/A | Filing | Aug 23, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| CORRESP | Letter to the SEC | Aug 9, 2022 | — |
| CERT | Filing | Aug 9, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| CORRESP | Letter to the SEC | Aug 8, 2022 | — |
| 8-A12B | Filing | Aug 2, 2022 | — |
| CORRESP | Letter to the SEC | Jul 27, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2022 | — |
| CORRESP | Letter to the SEC | Jun 16, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2022 | — |
| CORRESP | Letter to the SEC | May 25, 2022 | — |
| UPLOAD | Letter from the SEC | May 10, 2022 | — |
| CORRESP | Letter to the SEC | Apr 25, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2022 | — |
| DRS | Filing | Feb 14, 2022 | — |
| D | Filing | Jul 26, 2017 | — |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.